Polypeptide and pharmaceutical composition containing the polypeptide

A composition and drug technology, applied in the field of pharmaceutical compositions containing the polypeptide, can solve the problems of angiogenesis and symptom deterioration, and achieve the effects of reducing manufacturing costs and excellent stability

Inactive Publication Date: 2011-02-16
HOKKAIDO UNIVERSITY +1
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, it is known that in certain diseases, for some reason, the regulation fails, causing undesired angiogenesis and exacerbation of symptoms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide and pharmaceutical composition containing the polypeptide
  • Polypeptide and pharmaceutical composition containing the polypeptide
  • Polypeptide and pharmaceutical composition containing the polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] 1) Preparation of cDNA encoding PEDF

[0077] According to the description of Yamagishi et al. (Biochem. Biophys. Res. Commun., 2002, Vol. 296, pp. 877-882), PCR was correlated with the human placenta cDNA library (Clontech Laboratories, Inc.) by using a pair of The primer DNA was carried out.

[0078] Primer 1F: 5'-CTCAGTGTGCAGGCTTAGAG-3' (SEQ ID NO: 7)

[0079] Primer 1R: 5'-CCTTCGTGTCCTGTGGAATC-3' (SEQ ID NO: 8)

[0080] The amplified product of about 1300bp was collected from the agarose gel and ligated to the SmaI site of pBluescriptIIKS. The constructs thus obtained were confirmed by restriction enzyme digestion and sequencing. The above-mentioned vector was cut with XbaI and HindIII and fragments were collected, which were then cloned between the NheI site (blunt end) and the XbaI site of pBK-CMV (Stratagene Corporation), thereby obtaining the pBK-CMV-PEDF plasmid, which is an expression vector with cDNA encoding PEDF.

[0081] 2) Preparation of polypeptides...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed is a novel polypeptide which can inhibit angiogenesis. Also disclosed is use of the polypeptide. The polypeptide comprises at least one amino acid sequence selected from the amino acid sequences depicted in SEQ ID NOs: 1-3, is composed of 120 or less amino acid residues, and has an anti-angiogenic activity. The polypeptide has an anti-angiogenic activity, has a lower molecular weight compared with that of PEDF, and has excellent penetration or absorption into a living body, particularly an affected part in a living body.

Description

technical field [0001] The present invention relates to a polypeptide capable of effectively treating or preventing diseases involving angiogenesis, an anti-angiogenesis agent containing the polypeptide as an active ingredient, or a pharmaceutical composition containing the polypeptide. Background technique [0002] In humans, angiogenesis is induced only at the right time or place under the tight control of a functional balance between angiogenic-promoting and anti-angiogenic factors, eg, during wound healing and specific phases of the menstrual cycle. [0003] However, it is known that, in certain diseases, the above-mentioned regulation fails for some reason, leading to undesired angiogenesis and exacerbation of symptoms. For example, in diabetic retinopathy and age-related macular degeneration, neovascularization in the iris, retina or optic nerve has been observed, and this is known to cause severe vision loss. Furthermore, angiogenesis is also known to be induced in s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61P35/00A61P27/02A61K38/00C12N15/00A61P29/00A61P19/02A61P9/00C07K14/47A61P17/06A61P9/10A61P17/00
CPCA61K38/00C07K14/811A61P17/00A61P17/06A61P19/02A61P27/02A61P29/00A61P35/00A61P9/00A61P9/10
Inventor 阿部理一郎清水宏中村和生松井孝宪今泉勉山岸昌一
Owner HOKKAIDO UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap